U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Enforcement Activities | FDA
  5. FDA Actions to Remove Unapproved Drugs from the Market by Company
  1. Enforcement Activities | FDA

FDA Actions to Remove Unapproved Drugs from the Market by Company

Acella Pharmaceuticals LLC 

  • Firm press release: Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Two Lots of NP Thyroid®, Thyroid Tablets, USP Due to Sub Potency (September 17, 2020)
  • Warning letter (August 14, 2020)
  • Firm news release: Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Certain Lots of NP Thyroid (Thyroid Tablets, USP) Due to Super Potency (May 22, 2020)

Acino Products LLC

AIG Technologies

Allay Pharmaceuticals, LLC

Azurity Pharmaceuticals Inc.

Better Rx LLC

BioDiagnostic International

  • FDA news release: FDA advises health care professionals not to use MedGyn Products’ Monsel’s Solution (June 29, 2018)
  • Warning letter (July 12, 2018)

Contacare Ophthalmics & Diagnostics

Crown Laboratories Inc.

Dercher Enterprises, Inc. dba Gordon Laboratories

GenPak Solutions LLC

Genus Medical Technologies

Humco Holding Group Inc.

Iso-Tex Diagnostics Inc.

Izeen Pharma Inc.

Kirkman Laboratories, Inc.

Medical Supply Liquidators LLC

Nationwide Laboratories, LLC

Rainbow Gold Products Inc.

RLC Labs Inc.

Sichuan Friendly Pharmaceutical Co., Limited and Westminster Pharmaceuticals LLC

  • FDA news release: FDA alerts drug makers of a recall of porcine thyroid API from Sichuan Friendly Pharmaceutical Co., Limited, China (August 17, 2018)

Stratus Pharmaceuticals, Inc. and Sonar Products, Inc.

Torrent Pharma, Inc.

Vista Pharmaceuticals Limited

Back to Top